Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

AR, Sánchez-Paulete; FJ, Cueto; M, Martínez-López; S, Labiano; A, Morales-Kastresana; ME, Rodríguez-Ruiz; ME, Rodríguez-Ruiz; M, Jure-Kunkel; A, Azpilikueta; MA, Aznar; JI, Quetglas; D, Sancho; I, Melero

doi:10.1158/2159-8290.cd-15-0510

Public

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Shared by NobleBlocks on Oct 22, 2015 • 12:00 AM UTC

Authors:

Sánchez-Paulete AR

Cueto FJ

Martínez-López M

Abstract

<h4>Unlabelled</h4>Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be rescued by immunomodulatory mAbs targeting PD-1 or CD137. Using Batf3(-/-) mice, which are defective for cross-presentation of cell-associated antigens, we show that BATF3-dependent dendritic cells (DC) a...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!